Notwithstanding promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from PBMs. Such insurers are frequently erecting barriers to coverage, such as steep expense requirements and PA that restrict consumer access. Analysts suggest that the c… Read More